Trends in Asthma Exacerbations at the Population Level Following the Adoption of Respiratory Biologics
Overview
This study investigates the population-level changes in asthma exacerbation trends following the introduction of respiratory biologics.
Background
Asthma is a significant global health issue, particularly for patients with severe asthma who experience high morbidity and mortality. The introduction of monoclonal antibodies (biologics) has provided an alternative to systemic corticosteroids, which carry substantial long-term risks.
Data Highlights
No numerical data or trial data provided in the source material.
Key Findings
The study included patients aged 18 years and older with physician-diagnosed asthma from a large healthcare system.
Exacerbations were defined as acute worsening requiring emergency visits, hospital admissions, or corticosteroid prescriptions.
Interrupted time series models were used to estimate trends in exacerbation rates before and after the introduction of biologics.
Baseline covariates included demographic characteristics and laboratory variables such as blood eosinophil counts.
Race and ethnicity were considered due to known disparities in biologic therapy utilization.
Clinical Implications
The findings emphasize the importance of monitoring asthma exacerbation trends in relation to the use of biologics. Clinicians should consider demographic factors when evaluating treatment effectiveness and access to biologic therapies.
Conclusion
The study provides insights into the trends of asthma exacerbations at the population level following the introduction of respiratory biologics.
